non-invasive prenatal testing for trisomies ... - ninalia nipt · non-invasive prenatal testing for...
TRANSCRIPT
Non-Invasive Prenatal Testing for trisomies 21, 18 and 13 (NIPT)The prenatal trisomy screening test based on a simple maternal blood sample
DS
29-IN
TGB
-HP
- Aug
ust 2
017
Brochure for healthcare professionals
2/5
DS
29-IN
TGB
-HP
- Aug
ust 2
017
What is the Ninalia screening test?
Ninalia Non-Invasive Prenatal Testing (NIPT) is an innovative genetic screening test that detects the main fœtal aneuploidies i.e. trisomy 21, 18 or 13 in pregnant women at risk from these pathologies.
The non-invasive screening test uses cell-free DNA from a maternal blood sample, ensuing no risk to the fœtus.
In many cases, NIPT eliminates the need for invasive sampling, thus reducing the associated risk to the foetus.*
* Non-invasive prenatal testing of trisomies 21, 18 and 13 could make 95% of invasive tests, (with an associated risk of miscarriage of around 0.5 to 1%), redundant (source: French National College of Gynaecologists and Obstetricians (CNGOF))
What is cell-free DNA?During pregnancy, the placenta releases cell-free DNA which circulates in the maternal blood stream.
As a result, maternal blood contains a mix of fœtal and maternal DNA in varying proportion. This proportion is the fœtal fraction.
Our laboratory isolates this circulating DNA in order to detect the presence of genetic material relating to chromosomes 21, 18 or 13.
If the fetal fraction is too low, a new sample may be required for analysis.
What is the technology used?Since october 2014, Eurofins Biomnis has chosen to collaborate with the company Illumina, a world leader in DNA sequencing, for non-invasive screening for the main chromosomal abnormalities.
The new VeriSeq NIPT method offers improved performances in order to enhance patient care.
Cell-free maternal DNA Cell-free fœtal DNA
3/5
DS
29-IN
TGB
-HP
- Aug
ust 2
017
Ninalia performance An excellent detection rate of Ninalia : 99%
Extremely low failure rate: 0.68%*
Short turnaround time: 5 business days A complete marked solution
Who should avail of the Ninalia screening test?Eurofins Biomnis follows the International recommendations of the American Congress of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) in relation to the indications for non-invasive prenatal screening for patients with a greater risk.
MAIN RECOMMENDATIONS(absence of ultrasound abnormalities)
Risk greater than 1/1000 according to maternal serum markers
Mothers aged ≥ 38 years for patients that did not benefit from the maternal serum markers
assay
History of pregnancy with foetal aneuploidies
Relative is carrier of a Robertsonian translocation involving chromosome 13 or 21
Twin pregnancy
1st line screening
*Data from the supplier Illumina, February 2017.
Down syndrome
99%*
99,9%*
Sensitivity
Specificity
4/5
DS
29-IN
TGB
-HP
- Aug
ust 2
017
Diagnostic strategy for T21
From 10 weeksof pregnancy 1 single blood draw
Shipment to Eurofins Biomnis France
Results sent to healthcare prescriber within 5 business days*
Sample collection by the healthcare provider
Analysis of the mainfœtal aneuploidies:trisomies 21, 18 and 13
Eurofins Biomnis’ geneticists are available to advisehealthcare provider, if required
Medical consultationand Ninaliaprescription
Negative resultPositive result
Confirmation of the diagnosis by fœtal karyotype testing on an invasive sample
Conventional medical and
ultrasound follow-up
Absence of ultrasound abnormalities
Non-invasive prenatal screening for Down syndrome, Edwards' syndrome and Patau syndrome
High risk Medium risk Other cases
Combined screening for Down syndromeUltrasound and Maternal Serum Markers
Step by step guide to Ninalia
What does Ninalia screen for?It screens for the main fetal aneuploidies i.e. trisomy 21, 18 and 13.
Depending on local regulation, the test also provides optional fœtal gender and sex chromosomes aneuploidies.
For any further information, please contact Eurofins Biomnis International Division at :
* For example, if the sample is received in Eurofins Biomnis on a Tuesday, the results will be sent to the healthcare provider the following Monday
5/5
To know more about Ninalia and to order the sampling kit, please visit:
www.nipt-biomnis.com
INTE
RN
ATIO
NA
L G
B
Eurofins BiomnisInternational Division17/19 av. Tony Garnier BP 7322 - 69357 LYON Cedex 07 FRANCE
E-mail: [email protected]
About Eurofins Biomnis Eurofins Biomnis, European leader in specialised medical pathology, has its origins in the laboratory established by Marcel Mérieux in 1897. Its primary focus is the performance of highly specialised analyses requiring the use of high-expertise test procedures.
Eurofins Biomnis is active in all fields of medical pathology, in particular fœtal biochemistry and prenatal diagnostics.
Geneticists, qualified in prenatal diagnosis and responsible for Eurofins Biomnis tests are available to prescribers to provide the best possible support in the implementation of this
genetic test.
Ninalia : at a glance NIPT stands for Non-Invasive Prenatal
Testing
Ninalia NIPT is a screening test for pregnant women at risk of trisomy 21, 18 and 13.
It is without risk to fœtus since this test requires a simple maternal blood draw collected by healthcare providers
Ninalia can be performed from 10 weeks of pregnancy
Results are sent to healthcare providers within 5 business days upon reception at Eurofins Biomnis
Highly accurate test with a detection rate of 99% and an extremely low failure rate
Over 15,000 Ninalia tests have been performed to date
Ninalia is NF EN ISO 15189 accredited*
The assurance of Eurofins Biomnis expertise. The laboratory is based in France and is the European leader in specialised medical pathology.
*Accreditation delivered by the Cofrac (N#8-1973 & N#8-1110, available on www.cofrac.fr) D
S29
-INTG
B-H
P - A
ugus
t 201
7 - ©
123R
F/Jo
zef P
olc/
Ast
roid
/Atic
12/A
nna
Ivan
ova